Board of Directors

Peter Benson is co-founder and Managing Partner of Sunstone Capital Life Science Ventures and chairman of Alligator Bioscience AB, which is listed on Nasdaq Stockholm. Peter Benson has extensive experience from the Life Science sector as an investor, board member and in management positions, including in several listed companies. Peter Benson was vice chairman of Zealand Pharma during its IPO and has previously inter alia been Head of Life Science Ventures at Vækstfonden (the Danish Growth Fund), President of Hospital Care and Senior Vice President at Pharmacia as well as Vice President Marketing & Sales at Kabi Pharmacia Parenterals.

Graduate in business administration from Lund University, Sweden. MA in Economics from the University of California, US.

Chairman of Alligator Bioscience AB (publ), Ascelia Incentive AB, Good Partners Media Group AB and Sunstone LSV Partners Holding ApS. Board member of Adenium Biotech ApS, Arcoma Aktiebolag, CMC SPV of 3 April 2017 AB, Jollingham AB, Montela Aktiebolag, Opsona Therapeutics Ltd. and Sunstone Capital A/S (and subsidiaries within the Sunstone Capital A/S sphere). Deputy board member of JellyBean Aktiebolag.

-

Independent in relation to the Company and its management, but not in relation to major shareholders. Managing Partner of Sunstone Life Science Venture A/S and board member of CMC SPV of 3 April 2017 AB.

Bo Jesper Hansen has extensive experience from orphan drug research and development, international marketing and business development. Bo Jesper Hansen is and has previously been chairman and member of the board of directors in a number of biotech and pharma companies, including executive chairman of Swedish Orphan Biovitrum AB (publ), Topotarget A/S (publ) and Karolinska Development AB (publ) and chairman of Ablynx nv (publ).

M.D. and Ph.D. from University of Copenhagen, Denmark.

Chairman of Innoventa Medica ApS and Laborie Inc. Board member of Azanta A/S. Vice-chairman of Orphazyme ApS.

216,164 shares in Ascelia Pharma AB. Bo Jesper Hansen also holds approximately 4 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia Pharma AB.

Independent in relation to the Company and its management, but not in relation to major shareholders. Shareholder in CMC SPV of 3 April 2017 AB.

Hans Maier has held senior positions within Schering AG and Bayer AG in Europe and Asia, inter alia as Managing Director in Korea and in Japan, Head of Corporate Strategy and Business Development of Schering AG and Head of the Global Business Unit Diagnostic Imaging in both Schering AG and Bayer AG. Hans Maier is member of several advisory boards, inter alia the Fraunhofer Institute for Medical Image Computing and the German Heart Center Berlin. Hans Maier is a member of several supervisory and advisory boards, including the German Heart Center Berlin (President of the Board of Trustees) and the Fraunhofer Mevis Institute for Medical Image Computing (Chairman of the Advisory Board).

Ph.D. in Economics and Social Sciences and Degree in Political Science from Freie Universität Berlin, Germany.

Board member of Deutsches Herzzentrum Berlin and Fraunhofer Institute for Medical Image Computing MEVIS. Co-Founder and Managing Partner of BGM Associates GmbH.

10,000 shares in Ascelia Pharma AB.

Independent in relation to the Company and its management, and in relation to major shareholders.

Niels Mengel is Founding Partner, board member and CEO of Øresund-Healthcare Capital. Niels Mengel has extensive experience from the healthcare industry as an investor. Niels Mengel has previously inter alia been Executive Vice President at ISS World Services A/S and Director at PA Consulting Group.

M.B.A. from London Business School, England. M.Sc. in Macro Economy and Finance from University of Copenhagen, Denmark.

Chairman of Dansk Aktionærforening. Board member of Better Finance (The European Federation of Investors and Financial Services Users), Black Swan Strategy A/S and Upstream Invest A/S. Board member and managing partner of Øresund-Healthcare Management A/S. Limited partner of Øresund-Healthcare Capital K/S. Partner of ØHM Exit I I/S and ØHM Exit II I/S. Member of management (executive) in Kibegeon ApS.

Niels Mengel, has directly and indirectly, invested in Øresund-Healthcare Capital K/S that holds (i) 2,020,459 shares in Ascelia Pharma AB and (ii) approximately 5 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia Pharma AB. Through the agreements governing Niels Mengel’s investments in Øresund-Healthcare Capital K/S, Niels Mengel has a financial interest corresponding to (a) approximately 50 per cent of the shares in Ascelia Pharma AB held by Øresund-Healthcare Capital K/S and (b) 100 per cent of the shares in CMC SPV of 3 April 2017 AB held by Øresund-Healthcare Capital K/S.

Independent in relation to the Company and its management, but not in relation to major shareholders. Founding partner of Øresund-Healthcare Capital K/S.

René Spogárd is chairman and investor in a number of companies including JEKA Fish A/S, Bollerup Jensen A/S and Flex Funding A/S. René Spogárd has extensive experience from investing in the healthcare sector and board positions in a public environment. René Spogárd has previously inter alia been owner and Managing Director at TNS Gallup A/S and Director at TNS plc (listed on London Stock Exchange).

H.D. in Marketing from Copenhagen Business School, Denmark.

Chairman of Ambrox Property Invest III A/S, Bollerup Jensen A/S, Bollerup Jensen Adhesives ApS, Bollerup Jensen Water Holding ApS, CMC SPV of 3 April 2017 AB, Cimbric A/S, Deltaq Portefølje Holding 104 ApS, Deltaq Portefølje Holding II ApS, Deltaq Portefølje Holding IV ApS, Deltaq Portefølje Holding VI ApS, Flex Funding A/S, Jeka Fish A/S, Jeka Fish Holding ApS, Jeka Fish Holding 2 ApS, Jysk Industri Holding A/S and Preservation Technologies I/S. Deputy chairman of Nordisk Krabbe Kompagni A/S. Board member of Ambrox Capital A/S, Ambrox Korsør A/S, Bollerup Jensen Adhesives Holding ApS, Bollerup Jensen Water ApS, Bollerup Jensen Wood ApS and Flex Funding Fintech ApS. Member of management (executive) and partner of Dadephi ApS, René Spogárds amilieanpartsselskab, Spogárd Holding ApS, Spogárd Invest ApS and Spogárd Invest 3 ApS.

333,418 shares in Ascelia Pharma AB indirectly through company. René Spogárd also indirectly holds approximately 24 per cent of the shares in CMC SPV of 3 April 2017 AB that holds 2,937,606 shares in Ascelia Pharma AB.

Independent in relation to the Company and its management, but not in relation to major shareholders. Shareholder in and chairman of the board of directors of CMC SPV of 3 April 2017 AB.

Helena Wennerström has been Executive Vice President of Bulten AB (publ) since 2014 and has been its Chief Financial Officer since 2006. Helena Wennerström's work within Bulten AB also includes the Investor Relations and Communications activities and IT. Helena Wennerström has earlier served finance roles at Digitalfabriken and Topcon.

Master of Science in Business Administration and Economics from Örebro University.

Chairman of Bulten Fasteners AB. Board member of Bulten Hallstahammar AB, Bulten North America LLC, Bulten Polska S.A., Bulten Sweden AB, Bulten Fasteners (China) Co Ltd. and BBB Services Ltd. Deputy board member of Bulten Industrifastighet AB, Finnveden Micro Fasteners AB and Finnveden Trading Aktiebolag. Deputy Managing Director of Bulten AB.

8,000 shares in Ascelia Pharma AB.

Independent in relation to the Company and its management, and in relation to major shareholders.